Mirova’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mirova’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,846	Closed	-$191K	–	173
2022 Q4	$191K	Sell	1,846 -1	-0.1%	-$94	0.03%	166
2022 Q3	$156K	Buy	+1,847	New	+$164K	0.03%	161
2022 Q2	–	Sell	-4,522	Closed	-$348K	–	181
2022 Q1	$348K	Sell	4,522 -265	-6%	-$22.2K	0.05%	136
2021 Q4	$422K	Buy	+4,787	New	+$395K	0.05%	127

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mirova's BMRN Position: Q1 2023 in Review

Mirova sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 1,846 shares — an estimated $191K sold.

Mirova first reported a position in BMRN in Q4 2021 and held it in 4 quarters. The position peaked at $422K in Q4 2021. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Mirova reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Mirova sold 1,846 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $191K.
Mirova first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Mirova's BioMarin Pharmaceuticals position peaked at $422K in Q4 2021.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Mirova's 13F filing for Q1 2023, filed 12 May 2023.